Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - pregabalinum - capsule rigide - pregabalinum 200 mg, lactosum monohydricum 22 mg, maydis amylum, talcum, kapselhülle: gelatina, aqua, e 171, e 172 (rubrum), natrii laurilsulfas corresp. natrium 0.012 mg, silica colloidalis anhydrica, drucktinte: lacca, e 172 (nigrum), propylenglycolum, kalii hydroxidum pro capsula. - antiepilepticum, dolore neuropatico, disturbo d'ansia generalizzata - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - gabapentinum - capsule - gabapentinum 100 mg, excipiens pro capsula. - antiepilepticum, in caso di dolore neuropatico - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - gabapentinum - capsule - gabapentinum 300 mg, excipiens pro capsula. - antiepilepticum, in caso di dolore neuropatico - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - gabapentinum - capsule - gabapentinum 400 mg, excipiens pro capsula. - antiepilepticum, in caso di dolore neuropatico - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - lenalidomidum - capsule rigide - lenalidomidum 2.50 mg, amylum pregelificatum, cellulosum microcristallinum, carmellosum natricum conexum, silica colloidalis anhydrica, natrii stearylis fumaras, kapselhülle: e 172 (flavum), titanii dioxidum, e 132, gelatina, drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula corresp. natrium 0.411 mg. - onkologikum - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - lenalidomidum - capsule rigide - lenalidomidum 7.5 mg, amylum pregelificatum, cellulosum microcristallinum, carmellosum natricum conexum, silica colloidalis anhydrica, natrii stearylis fumaras, kapselhülle: e 172 (flavum), titanii dioxidum, e 172 (nigrum), gelatina, drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula corresp. natrium 0.506 mg. - onkologikum - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - sunitinibum - capsule rigide - sunitinibum 25 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium, povidonum, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - farmaco - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - sunitinibum - capsule rigide - sunitinibum 50 mg, cellulosum microcristallinum, mannitolum, carmellosum natricum conexum corresp. natrium, povidonum, magnesii stearas, kapselhülle: e 172 (nigrum), e 172 (rubrum), e 172 (flavum), e 171, gelatina, drucktinte: lacca, e 171, propylenglycolum, pro capsula. - farmaco - synthetika

Europeiska unionen - italienska - EMA (European Medicines Agency)

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - immunosoppressori - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Europeiska unionen - italienska - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - farmaci usati nel diabete - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.